Northern Biologics’ Rahul Ballal Joins Imara as CEO

Xconomy Boston — 

Rahul Ballal has been named CEO of Cambridge drug developer Imara. Ballal most recently served as chief business officer of Northern Biologics. Imara launched in 2016 backed by $31 million in financing to develop drugs for sickle cell disease and other blood disorders. The company’s lead sickle cell disease compound, IMR-687, is in mid-stage clinical studies.